Royalty Pharma CEO granted 157,828 Class A shares

Royalty Pharma CEO Pablo G. Legorreta acquired 157,828 Class A Ordinary Shares at $0.00 per share on February 11, 2026 through the settlement of equity performance awards.

Rhea-AI Filing Summary

Royalty Pharma CEO Pablo G. Legorreta acquired 157,828 Class A Ordinary Shares at $0.00 per share on February 11, 2026 through the settlement of equity performance awards. Following this exempt award, he directly holds 1,098,783 Class A Ordinary Shares.

He also has indirect ownership through various family trusts and entities, including Legorreta Children 2002 Trust, GST-Exempt Legorreta family trusts, Legorreta Investments LLC, Tata MC 35 Ltd., and accounts for spouse and children. In addition, he and related vehicles hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 73,495,660 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 13,356,742 Class A Ordinary Shares, with the Class E shares subject to vesting conditions.

Insider Trade Summary

Grant/Award: 157,828 shares

Grant/Award 12 txns

Insider Legorreta Pablo G.

Role CEO, Chairman of the Board

Type	Security	Shares	Price	Value
Grant/Award	Class A Ordinary Shares	157,828	$0.00	$0.00
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--
holding	Class A Ordinary Shares	--	--	--

Holdings After Transaction: Class A Ordinary Shares — 1,098,783 shares (Direct); Class A Ordinary Shares — 1,040,410 shares (Indirect, By Legorreta Children 2002 Trust); Class A Ordinary Shares — 901,590 shares (Indirect, By GST-Exempt Legorreta 2012 Family Trust); Class A Ordinary Shares — 600,000 shares (Indirect, By Legorreta 2023 SR Trust); Class A Ordinary Shares — 460,139 shares (Indirect, By Legorreta Investments LLC); Class A Ordinary Shares — 292,190 shares (Indirect, By Tata MC 35 Ltd.); Class A Ordinary Shares — 123,310 shares (Indirect, By IRRA); Class A Ordinary Shares — 118,500 shares (Indirect, By SEP/IRA); Class A Ordinary Shares — 41,306 shares (Indirect, By GST-Exempt Legorreta 2020 Family Trust); Class A Ordinary Shares — 10,000 shares (Indirect, By Son); Class A Ordinary Shares — 10,000 shares (Indirect, By Daughter); Class A Ordinary Shares — 6,930 shares (Indirect, By Spouse)

Footnotes (1)

1. F1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Royalty Pharma (RPRX) report for Pablo G. Legorreta?

Royalty Pharma reported that CEO Pablo G. Legorreta acquired 157,828 Class A Ordinary Shares at $0.00 per share. The shares were received as an exempt equity performance award settlement, increasing his direct Class A Ordinary Share holdings to 1,098,783 after the transaction.

How did Pablo G. Legorreta receive the 157,828 Royalty Pharma (RPRX) shares?

He received 157,828 Class A Ordinary Shares in an exempt acquisition under Rule 16b-3. The shares were granted in connection with the settlement of equity performance awards, meaning they were compensation-based and not open-market purchases for cash consideration.

How many Royalty Pharma (RPRX) shares does Pablo G. Legorreta now own directly?

After the February 11, 2026 equity award, Pablo G. Legorreta directly owns 1,098,783 Class A Ordinary Shares. This figure reflects his direct beneficial ownership only and does not include additional indirect holdings through family trusts, entities, or other related investment vehicles.

What indirect Royalty Pharma (RPRX) holdings are associated with Pablo G. Legorreta?

Indirect holdings include Class A Ordinary Shares held through family trusts and entities such as the Legorreta Children 2002 Trust, GST-Exempt Legorreta family trusts, Legorreta Investments LLC, Tata MC 35 Ltd., and accounts for spouse and children, each reported as indirect beneficial ownership.

What exchangeable interests tied to Royalty Pharma (RPRX) does Pablo G. Legorreta report?

He and related family vehicles hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 73,495,660 Class A Ordinary Shares. They also hold Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 13,356,742 Class A Ordinary Shares, with those Class E shares subject to vesting conditions.

Was the Royalty Pharma (RPRX) insider transaction a buy or a grant?

The transaction was a grant, not an open-market buy. It is reported with transaction code A as an exempt acquisition of 157,828 Class A Ordinary Shares in connection with equity performance awards, with no cash price paid per share in the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Legorreta Pablo G.

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 E. 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO, Chairman of the Board

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	02/11/2026		A		157,828(1)	A	$0	1,098,783	D
Class A Ordinary Shares								1,040,410	I	By Legorreta Children 2002 Trust
Class A Ordinary Shares								901,590	I	By GST-Exempt Legorreta 2012 Family Trust
Class A Ordinary Shares								600,000	I	By Legorreta 2023 SR Trust
Class A Ordinary Shares								460,139	I	By Legorreta Investments LLC
Class A Ordinary Shares								292,190	I	By Tata MC 35 Ltd.
Class A Ordinary Shares								123,310	I	By IRRA
Class A Ordinary Shares								118,500	I	By SEP/IRA
Class A Ordinary Shares								41,306	I	By GST-Exempt Legorreta 2020 Family Trust
Class A Ordinary Shares								10,000	I	By Son
Class A Ordinary Shares								10,000	I	By Daughter
Class A Ordinary Shares								6,930	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Remarks:

In addition to the Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 73,495,660 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd ("RPH") exchangeable into 13,356,742 Class A Ordinary Shares. Class E Ordinary Shares of RPH are subject to vesting conditions.

	/s/ Sean Weisberg, as Attorney-in-Fact for Pablo G. Legorreta	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.